Purchase by Matthew Foehr of 95000 shares of OmniAb
| OABI Stock | USD 3.52 0.07 1.95% |
Under 61% of OmniAb's investor base is looking to short. The analysis of the overall investor sentiment regarding OmniAb Inc suggests that many traders are alarmed. OmniAb's investing sentiment shows overall attitude of investors towards OmniAb Inc.
OmniAb |
Filed transaction by Omniab Inc director. General open market or private purchase of non-derivative or derivative security
Read at macroaxis.com
OmniAb Fundamental Analysis
We analyze OmniAb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OmniAb using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OmniAb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
OmniAb is currently under evaluation in target price category among its peers.
OmniAb Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OmniAb stock to make a market-neutral strategy. Peer analysis of OmniAb could also be used in its relative valuation, which is a method of valuing OmniAb by comparing valuation metrics with similar companies.
Peers
OmniAb Related Equities
| PASG | Passage Bio | 1.92 | ||||
| VRNA | Verona Pharma | 1.81 | ||||
| PMVP | Pmv Pharmaceuticals | 1.42 | ||||
| ITOS | Iteos Therapeutics | 1.29 | ||||
| ACET | Adicet Bio | 1.12 | ||||
| EWTX | Edgewise Therapeutics | 0.28 | ||||
| KROS | Keros Therapeutics | 0.27 | ||||
| IDYA | Ideaya Biosciences | 0.48 | ||||
| ERAS | Erasca | 0.71 | ||||
| GLUE | Monte Rosa | 1.03 | ||||
| OLMA | Olema Pharmaceuticals | 1.29 | ||||
| CGEM | Cullinan Oncology | 1.29 | ||||
| LEGN | Legend Biotech | 1.30 | ||||
| IPSC | Century Therapeutics | 1.43 | ||||
| IKNA | Ikena Oncology | 2.14 | ||||
| VOR | Vor Biopharma | 4.55 | ||||
| BCAB | Bioatla | 10.53 |
Complementary Tools for OmniAb Stock analysis
When running OmniAb's price analysis, check to measure OmniAb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OmniAb is operating at the current time. Most of OmniAb's value examination focuses on studying past and present price action to predict the probability of OmniAb's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OmniAb's price. Additionally, you may evaluate how the addition of OmniAb to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |